PTH(1-34) for Surgical Hypoparathyroidism: A Prospective, Open-Label Investigation of Efficacy and Quality of Life.

What Was Tested

Researchers studied Calcium and Vitamin D in this clinical trial publication.

The objective of the study was to investigate the effects of 6 months of PTH(1-34) treatment in adult subjects with postoperative hypoparathyroidism and to evaluate quality-of-life changes.

Why It Was Studied

Conventional therapy for hypoparathyroidism consists of calcium and calcitriol, but sometimes normal serum calcium cannot be maintained, and/or this approach might lead to nephrocalcinosis, nephrolithiasis, or renal insufficiency.

Who Took Part

The study group was 42 subjects.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

Quality of life was evaluated by the Rand 36-Item Short Form Health Survey covering eight domains of physical and mental health.

How the Study Was Run

The design is described as open-label and multicenter.

Being open-label, the Calcium study did not mask who received what.

Running at several centres spread the Calcium study over different clinics and patient groups.

This was a 2-year prospective, open-label study.

This was an Italian multicentric study.

What Was Measured

The subject headings attached to it are Alkaline Phosphatase, Calcium, Creatinine, Dietary Supplements, Hormone Replacement Therapy, Hypoparathyroidism and Parathyroid Hormone.

What This Means in Plain Language

The paper is an open-label and multicenter study of Calcium and Vitamin D in 42 subjects.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: all human trials.